vs
ARTIVION, INC.（AORT）与GLOBUS MEDICAL INC（GMED）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是ARTIVION, INC.的7.1倍（$826.4M vs $116.0M）。GLOBUS MEDICAL INC净利率更高（17.0% vs 2.1%，领先14.9%）。GLOBUS MEDICAL INC同比增速更快（25.7% vs 19.2%）。GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $-7.9M）。过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs 9.1%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
AORT vs GMED — 直观对比
营收规模更大
GMED
是对方的7.1倍
$116.0M
营收增速更快
GMED
高出6.5%
19.2%
净利率更高
GMED
高出14.9%
2.1%
自由现金流更多
GMED
多$210.3M
$-7.9M
两年增速更快
GMED
近两年复合增速
9.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $826.4M |
| 净利润 | $2.4M | $140.6M |
| 毛利率 | 63.1% | 68.4% |
| 营业利润率 | 9.2% | 20.5% |
| 净利率 | 2.1% | 17.0% |
| 营收同比 | 19.2% | 25.7% |
| 净利润同比 | 114.7% | 430.4% |
| 每股收益（稀释后） | $0.06 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTGMED
| Q4 25 | $116.0M | $826.4M | ||
| Q3 25 | $113.4M | $769.0M | ||
| Q2 25 | $113.0M | $745.3M | ||
| Q1 25 | $99.0M | $598.1M | ||
| Q4 24 | $97.3M | $657.3M | ||
| Q3 24 | $95.8M | $625.7M | ||
| Q2 24 | $98.0M | $629.7M | ||
| Q1 24 | $97.4M | $606.7M |
净利润AORTGMED
| Q4 25 | $2.4M | $140.6M | ||
| Q3 25 | $6.5M | $119.0M | ||
| Q2 25 | $1.3M | $202.8M | ||
| Q1 25 | $-505.0K | $75.5M | ||
| Q4 24 | $-16.5M | $26.5M | ||
| Q3 24 | $-2.3M | $51.8M | ||
| Q2 24 | $-2.1M | $31.8M | ||
| Q1 24 | $7.5M | $-7.1M |
毛利率AORTGMED
| Q4 25 | 63.1% | 68.4% | ||
| Q3 25 | 65.6% | 67.2% | ||
| Q2 25 | 64.7% | 66.6% | ||
| Q1 25 | 64.2% | 67.3% | ||
| Q4 24 | 63.2% | 59.9% | ||
| Q3 24 | 63.7% | 56.8% | ||
| Q2 24 | 64.6% | 58.7% | ||
| Q1 24 | 64.6% | 60.2% |
营业利润率AORTGMED
| Q4 25 | 9.2% | 20.5% | ||
| Q3 25 | 11.1% | 17.9% | ||
| Q2 25 | 7.4% | 10.2% | ||
| Q1 25 | 2.2% | 16.2% | ||
| Q4 24 | 2.7% | 9.2% | ||
| Q3 24 | 4.6% | 7.7% | ||
| Q2 24 | 6.6% | 7.9% | ||
| Q1 24 | 26.0% | 1.3% |
净利率AORTGMED
| Q4 25 | 2.1% | 17.0% | ||
| Q3 25 | 5.7% | 15.5% | ||
| Q2 25 | 1.2% | 27.2% | ||
| Q1 25 | -0.5% | 12.6% | ||
| Q4 24 | -16.9% | 4.0% | ||
| Q3 24 | -2.4% | 8.3% | ||
| Q2 24 | -2.2% | 5.0% | ||
| Q1 24 | 7.7% | -1.2% |
每股收益（稀释后）AORTGMED
| Q4 25 | $0.06 | $1.01 | ||
| Q3 25 | $0.13 | $0.88 | ||
| Q2 25 | $0.03 | $1.49 | ||
| Q1 25 | $-0.01 | $0.54 | ||
| Q4 24 | $-0.40 | $0.19 | ||
| Q3 24 | $-0.05 | $0.38 | ||
| Q2 24 | $-0.05 | $0.23 | ||
| Q1 24 | $0.18 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $557.2M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $4.6B |
| 总资产 | $884.8M | $5.3B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTGMED
| Q4 25 | $64.9M | $557.2M | ||
| Q3 25 | $73.4M | $18.8M | ||
| Q2 25 | $53.5M | — | ||
| Q1 25 | $37.7M | — | ||
| Q4 24 | $53.5M | $890.1M | ||
| Q3 24 | $56.2M | $71.9M | ||
| Q2 24 | $55.0M | $82.5M | ||
| Q1 24 | $51.1M | $80.4M |
总债务AORTGMED
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTGMED
| Q4 25 | $448.2M | $4.6B | ||
| Q3 25 | $438.7M | $4.4B | ||
| Q2 25 | $419.9M | $4.3B | ||
| Q1 25 | $294.3M | $4.1B | ||
| Q4 24 | $276.2M | $4.2B | ||
| Q3 24 | $304.7M | $4.1B | ||
| Q2 24 | $295.1M | $4.0B | ||
| Q1 24 | $295.0M | $3.9B |
总资产AORTGMED
| Q4 25 | $884.8M | $5.3B | ||
| Q3 25 | $857.7M | $5.1B | ||
| Q2 25 | $838.4M | $5.0B | ||
| Q1 25 | $791.2M | $4.7B | ||
| Q4 24 | $789.1M | $5.3B | ||
| Q3 24 | $803.1M | $5.1B | ||
| Q2 24 | $789.5M | $5.0B | ||
| Q1 24 | $784.0M | $4.9B |
负债/权益比AORTGMED
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $248.6M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $202.4M |
| 自由现金流率自由现金流/营收 | -6.9% | 24.5% |
| 资本支出强度资本支出/营收 | 23.7% | 5.6% |
| 现金转化率经营现金流/净利润 | 8.06× | 1.77× |
| 过去12个月自由现金流最近4个季度 | $839.0K | $588.8M |
8季度趋势，按日历期对齐
经营现金流AORTGMED
| Q4 25 | $19.6M | $248.6M | ||
| Q3 25 | $22.3M | $249.7M | ||
| Q2 25 | $15.0M | $77.9M | ||
| Q1 25 | $-17.0M | $177.3M | ||
| Q4 24 | $10.1M | $210.3M | ||
| Q3 24 | $11.5M | $203.7M | ||
| Q2 24 | $6.1M | $54.3M | ||
| Q1 24 | $-5.5M | $52.4M |
自由现金流AORTGMED
| Q4 25 | $-7.9M | $202.4M | ||
| Q3 25 | $17.7M | $213.9M | ||
| Q2 25 | $11.7M | $31.3M | ||
| Q1 25 | $-20.6M | $141.2M | ||
| Q4 24 | $8.7M | $193.2M | ||
| Q3 24 | $7.8M | $161.7M | ||
| Q2 24 | $3.6M | $26.5M | ||
| Q1 24 | $-9.1M | $23.8M |
自由现金流率AORTGMED
| Q4 25 | -6.9% | 24.5% | ||
| Q3 25 | 15.6% | 27.8% | ||
| Q2 25 | 10.4% | 4.2% | ||
| Q1 25 | -20.8% | 23.6% | ||
| Q4 24 | 9.0% | 29.4% | ||
| Q3 24 | 8.2% | 25.8% | ||
| Q2 24 | 3.7% | 4.2% | ||
| Q1 24 | -9.3% | 3.9% |
资本支出强度AORTGMED
| Q4 25 | 23.7% | 5.6% | ||
| Q3 25 | 4.1% | 4.7% | ||
| Q2 25 | 2.9% | 6.2% | ||
| Q1 25 | 3.7% | 6.0% | ||
| Q4 24 | 1.5% | 2.6% | ||
| Q3 24 | 3.8% | 6.7% | ||
| Q2 24 | 2.6% | 4.4% | ||
| Q1 24 | 3.7% | 4.7% |
现金转化率AORTGMED
| Q4 25 | 8.06× | 1.77× | ||
| Q3 25 | 3.42× | 2.10× | ||
| Q2 25 | 11.16× | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | — | 7.94× | ||
| Q3 24 | — | 3.93× | ||
| Q2 24 | — | 1.71× | ||
| Q1 24 | -0.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
